ClinicalTrials.gg
CompletedNCT00301236Updated Dec 21, 2007

Efficacy, Tolerability and Safety of Dexmethylphenidate HCl Extended-Release Capsules in Children With Attention-Deficit/Hyperactivity Disorder

A Phase 3 interventional study of Dexmethylphenidate HCl extended-release capsules in ADHD, ADD, sponsored by Novartis. Completed at 25 sites in United States. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2007-12-21.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis — none open to participants now, none under way, none of them phase 3. Attention Deficit Disorder with Hyperactivity · Novartis.

Enrollment
3rd of 10
252 · median 146
Started
2006
with 1 other
Phase 3
7 of 10
none open now
Registered
4th of 10
by date

Among the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis, this one is the 3rd largest by enrollment, is one of 2 that started in 2006, is one of 7 in phase 3, and was the 4th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

None of the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis is open now. The open studies under Attention Deficit Disorder with Hyperactivity, anywhere →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Attention Deficit Disorder with Hyperactivity by Novartis as a file.
02

Study summary

The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.

Read the detailed description

The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.

03

Conditions studied

  • ADHD, ADD

Keywords

  • ADHD, children, CADS-T, Dexmethylphenidate-HCl, extended release
04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children 6 - 12 with a diagnosis of ADHD of any type , Same teacher who is willing to complete the assessment during the school term

Exclusion criteria

Exclusion Criteria:

  • Previous cardiac problems of the patient or the parents or current cardiac findings of the patient; Relevant medical condition other than ADHD; ADHD medication within a specified timeperiod prior to study start; Pregnancy or nursing; Positive drug screen

Other protocol-defined inclusion/exclusion criteria may apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
252 participants
06

What researchers measure

Primary outcomes

  1. Assessment of the symptoms by the patient's teacher after 5 weeks of treatment.

Secondary outcomes

  1. Assessment of the symptoms by the patient's parent after five weeks of treatment.

  2. Change in severity of the illness assessed by the physician after 5 weeks of treatment

  3. Improvement of the illness assessed by the physician after 5 weeks of treatment

  4. Safety and tolerability of 5 week's treatment with dexmethylphenidate HCl extended-release capsules in children with Attention-Deficit/Hyperactivity Disorder by assessing the frequency of adverse findings

07

Study locations

25 sites
  • Novartis Investigational Site
    Mesa, Arizona 85210, United States
  • Novartis Investigational Site
    Little Rock, Arkansas 72205, United States
  • Novartis Investigational Site
    Los Angeles, California 90095, United States
  • Novartis Investigational Site
    Boulder, Colorado 80304, United States
  • Novartis Investigational Site
    Maitland, Florida 32751, United States
  • Novartis Investigational Site
    Orlando, Florida 32806, United States
  • Novartis Investigational Site
    Stone Mountain, Georgia 30083, United States
  • Novartis Investigational Site
    Libertyville, Illinois 60048, United States
  • Novartis Investigational Site
    Overland Park, Kansas 66211, United States
  • Novartis Investigational Site
    Prairie Village, Kansas 66206, United States
  • Novartis Investigational Site
    Cambridge, Massachusetts 02138, United States
  • Novartis Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novartis Investigational Site
    Piscataway, New Jersey 08855, United States
  • Novartis Investigational Site
    Toms River, New Jersey 08755, United States
  • Novartis Investigational Site
    New York, New York 10029, United States
  • Novartis Investigational Site
    New York, New York 10032, United States
  • Novartis Investigational Site
    Staten Island, New York 10305, United States
  • Novartis Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • Novartis Investigational Site
    Raleigh, North Carolina 27609, United States
  • Novartis Investigational Site
    Columbus, Ohio 43205, United States
  • Novartis Investigational Site
    Gresham, Oregon 97030, United States
  • Novartis Investigational Site
    Philadelphia, Pennsylvania 19149, United States
  • Novartis Investigational Site
    Jackson, Tennessee 38305, United States
  • Novartis Investigational Site
    Memphis, Tennessee 38119, United States
  • Novartis Investigational Site
    Houston, Texas 77007, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2006
First posted
Mar 10, 2006
Start
Feb 2006
CompletionActual
Nov 2006
Last update
Dec 21, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00301236
Lead sponsor
Novartis
First posted
Mar 10, 2006
Start date
Feb 2006
Completion
Nov 2006
Last update
Dec 21, 2007

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmethylphenidate

Start the discussion